Does vitamin B12 really do anything for autism? is a question that comes up many times in the practice of providing biomedical treatments
The average GLP-1 weight loss per month article provides realistic monthly benchmarks
This article explores the primary routes of administration, their coding implications, and the importance of accurate documentation
On legal and regulatory status: BPC-157 and TB-500 are not approved by the FDA or EMA for any human therapeutic use
Flags theoretical pathologic angiogenesis potential: PMC12446177 Evidence Summary Preclinical: IBD/colitis models: High remission rates, restored mucosal architecture, improved barrier function Tendon repair: Accelerated healing, improved tensile strength, reduced fibrosis Neurovascular: Sciatic nerve protection, enhanced blood vessel growth in nerve tissue Human data (emerging): Interstitial cystitis pilot (2024, n=12): 10/12 complete resolution, 2/12 at 80% improvement IV safety study (2025, n=2): no adverse effects on cardiac, hepatic, renal, or glucose biomarkers Knee pain retrospective (2021, n=17): 91.6% reported significant improvement No large-scale controlled trials published Safety: No immunosuppression or hormonal disruption in available data 2025 systematic review (HSS Journal): recommends caution due to limited high-quality clinical evidence 2025 narrative review: flags theoretical pathologic angiogenesis risk Stable in gastric acid (oral administration viable) No observed toxicity at therapeutic doses in published reports Foundational Reviews Sikiric P, Seiwerth S, et al
